Knowledge Library
Establishment of EGFR TKI-Resistant Tumor Models
Despite improvement in clinical outcomes observed with the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs), long-term prognosis remains unfavorable due to the development of either intrinsic or acquired resistance. Understanding the mechanisms underlying this resistance is vital for designing strategies to address this challenge, and one approach involves the establishment of …Read More >
iMN041: Prodrug with a Unique Antitumor Immune Response
WuXi AppTec scientists contributed to a research article in the journal Translational Medicine Communications which characterized the antitumor immune responses generated by iMN041, a prodrug of a DNA methyl transferase/ribonucleotide reductase inhibitor. This study also assessed the efficacy of iMN041 in mouse xenografts of human clear cell renal cell cancer, pancreatic cancer, and triple negative …Read More >
EML4-ALK Cell Lines and In Vivo Models
The EML4-ALK fusion gene occurs in approximately 5% of non-small-cell lung cancers (NSCLCs), making this oncogene an important drug target. The development of ALK tyrosine kinase inhibitors (ALK-TKIs) has been a major advance in treating NSCLC with this fusion gene, but acquired resistance to ALK-TKIs ultimately limits their use. To support the development of next-generation …Read More >
High-Dimensional Flow Cytometry Platform
High-dimensional (HD) flow cytometry allows researchers to perform deep phenotyping of immune cells at the single cell level with increased accuracy and sensitivity. This technology enables complex pathway characterization and data integration for the identification of biomarkers used in immunotherapy. WuXi AppTec offers a comprehensive panel of HD flow cytometry services, with more than 100 …Read More >
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts
The contribution of the X-ray crystallography team from our WuXi AppTec site in Germany was acknowledged in a recent study published in the journal Cancer Discovery. In this study, the authors show that compound STX-478, an allosteric PI3Kα inhibitor, selectively targets prevalent PI3Kα helical- and kinase-domain mutant tumors. STX-478 demonstrated robust efficacy in human tumor …Read More >
OncoWuXi Express: FaDu ATM Knockout Tumor model
OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we showcase our FaDu ATM KO tumor model. Introduction: As reported, several physiological processes, such as the production of reactive oxygen species during …Read More >
Immune-Avatar Humanized Tumor Models
To support antitumor efficacy testing and address the challenges of clinical translatability, WuXi AppTec offers extensive panels of immune-avatar humanized mouse models. Our platform includes hPBMC, hHSC, and hNK humanized models with enabling studies from our platform of over 1,700 CDX and PDX models. These well-established models cover multiple cancer types, including breast, lung, liver, …Read More >
Expanded Applications of PDX Models
Patient-derived xenografts (PDXs) represent a powerful platform for cancer drug screening and biomarker discovery and are considered the gold standard of in vivo models for their proven clinical relevance to human disease. WuXi AppTec offers a comprehensive platform of more than 1,400 well-annotated PDXs across 30 cancer types. We also provide expanded in vitro, ex …Read More >
Leveraging Animal Models to Combat Drug Resistance in Cancer Therapy
Cancer, globally recognized as a significant threat to public health, can be effectively controlled in its early stages through chemotherapy, targeted therapy, and immunotherapy, all of which inhibit tumor growth. However, an inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. Unraveling the underlying mechanisms of resistance is pivotal in overcoming …Read More >